title: Chronic myeloid leukaemia and sickle cell disease: could imatinib prevent vaso-occlusive crisis?
authors.forename: Katia
authors.initials: K
authors.lastname: Stankovic Stojanovic
authors.forename: Brigitte
authors.initials: B
authors.lastname: Thiolière
authors.forename: Elzbzieta
authors.initials: E
authors.lastname: Garandeau
authors.forename: Isabelle
authors.initials: I
authors.lastname: Lecomte
authors.forename: Claude
authors.initials: C
authors.lastname: Bachmeyer
authors.forename: François
authors.initials: F
authors.lastname: Lionnet
mesh_terms: D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001157:Arterial Occlusive Diseases / Q000209:etiology / Q000517:prevention & control*; D001549:Benzamides; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications*; D010349:Patient Compliance; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate